Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients.

[1]  I. D. de Boer,et al.  Triglyceride content of lipoprotein subclasses and kidney hemodynamic function and injury in adolescents with type 1 diabetes. , 2022, Journal of diabetes and its complications.

[2]  A. Sahebkar,et al.  Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022) , 2022, Cardiovascular Diabetology.

[3]  A. Janež,et al.  Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL , 2022, Medicina.

[4]  M. Rizzo,et al.  A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies , 2022, Metabolites.

[5]  A. Stefanović,et al.  Transforming Growth Factor-β1 and Receptor for Advanced Glycation End Products Gene Expression and Protein Levels in Adolescents with Type 1 Diabetes Mellitus , 2020, Journal of clinical research in pediatric endocrinology.

[6]  A. Stefanović,et al.  Factors associated with oxidative stress status in pediatric patients with type 1 diabetes mellitus , 2020, Journal of pediatric endocrinology & metabolism : JPEM.

[7]  A. Stefanović,et al.  Heparin-binding epidermal growth factor (EGF)-like growth factor in pediatric patients with type 1 diabetes mellitus , 2020, Growth factors.

[8]  T. Milenković,et al.  Hashimoto Thyroiditis and Dyslipidemia in Childhood: A Review , 2019, Front. Endocrinol..

[9]  M. Rizzo,et al.  Future perspectives of the pharmacological management of diabetic dyslipidemia , 2019, Expert review of clinical pharmacology.

[10]  A. Stefanović,et al.  Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. , 2019, Atherosclerosis.

[11]  A. Remaley,et al.  Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study , 2018, Cardiovascular Diabetology.

[12]  T. Wong,et al.  ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents , 2018, Pediatric diabetes.

[13]  A. Stefanović,et al.  Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease , 2018, Angiology.

[14]  T. Milenković,et al.  Effects of co-existing autoimmune diseases on serum lipids and lipoprotein subclasses profile in paediatric patients with type 1 diabetes mellitus. , 2018, Clinical biochemistry.

[15]  S. Uwaezuoke.  The role of novel biomarkers in predicting diabetic nephropathy: a review , 2017, International journal of nephrology and renovascular disease.

[16]  G. Sesti,et al.  Cardiovascular effects of glucagon‐like peptide‐1 receptor agonist therapies in patients with type 1 diabetes , 2017, Diabetes, obesity & metabolism.

[17]  N. Bogavac-Stanojević,et al.  Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease , 2014, Scandinavian journal of clinical and laboratory investigation.

[18]  M. Banach,et al.  Should low high-density lipoprotein cholesterol (HDL-C) be treated? , 2014, Best practice & research. Clinical endocrinology & metabolism.

[19]  M. Banach,et al.  Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level , 2014, Acta Diabetologica.

[20]  J. Skupień,et al.  Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria , 2013, Diabetes Care.

[21]  M. Pencina,et al.  A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? , 2013, International journal of cardiology.

[22]  M. Banach,et al.  The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective , 2013 .

[23]  N. Bogavac-Stanojević,et al.  Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized high-density lipoprotein particles. , 2011, Clinical biochemistry.

[24]  R. Wadwa,et al.  Lipid and Lipoprotein Profiles in Youth With and Without Type 1 Diabetes , 2008, Diabetes Care.

[25]  B. Widmer,et al.  Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[26]  M. Craig,et al.  Natural History and Risk Factors for Microalbuminuria in Adolescents With Type 1 Diabetes , 2006, Diabetes Care.

[27]  H. Parving,et al.  Microalbuminuria as an early marker for cardiovascular disease. , 2006, Journal of the American Society of Nephrology : JASN.

[28]  M. Rizzo,et al.  The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins , 2006, Cardiovascular Drugs and Therapy.

[29]  M. Rizzo,et al.  Should we measure routinely the LDL peak particle size? , 2006, International journal of cardiology.

[30]  D. Lackland,et al.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. , 2003, Kidney international.

[31]  T. Orchard,et al.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.

[32]  M. Cooper,et al.  Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. , 2000, Diabetes & metabolism.

[33]  M. Spiroski,et al.  Low density lipoprotein subclass distribution in children with diabetes mellitus. , 2008, Bratislavske lekarske listy.